<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2495">
  <stage>Registered</stage>
  <submitdate>16/09/2009</submitdate>
  <approvaldate>16/09/2009</approvaldate>
  <nctid>NCT00979251</nctid>
  <trial_identification>
    <studytitle>Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects</studytitle>
    <scientifictitle>A Randomized Open Label Study Comparing the Efficacy, Safety, and Tolerability of Oral Administration of Amantadine and Ribavirin With Oseltamivir Versus Oseltamivir to Influenza A Virus Infected Immunocompromised Subjects</scientifictitle>
    <utrn />
    <trialacronym>PO206</trialacronym>
    <secondaryid>ADS-TCAD-PO206</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Oseltamivir Phosphate
Treatment: drugs - ADS-8902

Experimental: ADS-8902 - Amantadine and Ribavirin administered with Oseltamivir phosphate

Active Comparator: Comparator - Oseltamivir Phosphate


Treatment: drugs: Oseltamivir Phosphate
Oseltamivir Phosphate, q8h

Treatment: drugs: ADS-8902
Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to clearing of viral shedding</outcome>
      <timepoint>Baseline, Days 2, 4, 6, 8, 10, 15 and 20</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to alleviation of influenza clinical symptoms</outcome>
      <timepoint>Baseline, Days 2, 4, 6, 8, 10, 15, 20, 38</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects who enter the study with mild to moderate influenza and progress to severe influenza</outcome>
      <timepoint>Baseline, Days 2, 4, 6, 8, 10, 15, 20, 38</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of subjects with a treatment-sensitive influenza A strain at baseline who develop a resistant strain during treatment</outcome>
      <timepoint>Baseline, Days 2, 4, 6, 8, 10, 15, 20</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and tolerability (adverse events (AEs), AEs resulting in treatment discontinuation, and Serious AEs)</outcome>
      <timepoint>Through day 210</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Confirmed influenza A by rapid antigen testing

          -  Immunocompromised as defined by recent solid organ or hematopoietic transplant,
             chronic graft vs. host disease, taking at least 2 immunosuppressants, undergoing
             chemotherapy, taking high dose chemotherapeutics, HIV positive

          -  Clinical diagnosis of influenza

          -  Onset of illness within 5 days

          -  Male and female subjects agree to contraception through 24 weeks after last dose</inclusivecriteria>
    <inclusiveminage>1</inclusiveminage>
    <inclusiveminagetype>Year</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Received more than 1 dose of antiviral agents

          -  Critically ill

          -  Creatinine clearance less than 80 mg/mL

          -  Females who are pregnant and males whose female partners are pregnant

          -  Received live attenuated virus vaccine within 3 weeks</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>2</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC</recruitmentstate>
    <hospital>Adamas Investigational Site - Darlinghurst</hospital>
    <hospital>Adamas Investigational Site - Herston</hospital>
    <hospital>Adamas Investigational Site - Sydney</hospital>
    <hospital>Adamas Investigative Site - Parkville</hospital>
    <hospital>Adamas Investigational Site - Melbourne</hospital>
    <postcode>NSW 2010 - Darlinghurst</postcode>
    <postcode>QLD 4029 - Herston</postcode>
    <postcode>QLD 4029 - Sydney</postcode>
    <postcode>3050 - Parkville</postcode>
    <postcode> - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Hawaii</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Dakota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Leiden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Adamas Pharmaceuticals, Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This Phase 2, open label, randomized study will investigate the virologic benefit, clinical
      efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus
      oseltamivir monotherapy for the treatment of all strains of influenza A in immunocompromised
      adult and pediatric subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00979251</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>